Compare Stocks: FLGC, FEMY, NVNO, and NXL

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
FEMY Femasys	$2.96 +8.4%	$3.36	$2.02 ▼ $22.20	$24.79M	-2.08	2.06 million shs	573,290 shs
FLGC Flora Growth	$4.71 -20.0%	$2.64	$5.86 ▼ $47.00	$4.93M	1.9	39,454 shs	463,870 shs
NVNO enVVeno Medical	$10.29 -1.0%	$10.72	$8.67 ▼ $39.20	$7.03M	1.1	15,186 shs	21,197 shs
NXL Nexalin Technology	$0.33 +0.5%	$0.38	$0.31 ▼ $2.00	$7.32M	4	150,372 shs	70,616 shs

7 Stocks That Will Be Magnificent in 2026

Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
FEMY Femasys	0.00%	+29.26%	-21.90%	-66.21%	-76.18%
FLGC Flora Growth	-20.03%	+142.78%	+188.96%	+10.18%	-76.92%
NVNO enVVeno Medical	0.00%	-5.19%	+1.78%	-3.65%	-74.87%
NXL Nexalin Technology	0.00%	-5.11%	-29.04%	-12.07%	-53.88%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
FEMY Femasys	$2.96 +8.4%	$3.36	$2.02 ▼ $22.20	$24.79M	-2.08	2.06 million shs	573,290 shs
FLGC Flora Growth	$4.71 -20.0%	$2.64	$5.86 ▼ $47.00	$4.93M	1.9	39,454 shs	463,870 shs
NVNO enVVeno Medical	$10.29 -1.0%	$10.72	$8.67 ▼ $39.20	$7.03M	1.1	15,186 shs	21,197 shs
NXL Nexalin Technology	$0.33 +0.5%	$0.38	$0.31 ▼ $2.00	$7.32M	4	150,372 shs	70,616 shs

7 Stocks That Will Be Magnificent in 2026

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
FEMY Femasys	0.00%	+29.26%	-21.90%	-66.21%	-76.18%
FLGC Flora Growth	-20.03%	+142.78%	+188.96%	+10.18%	-76.92%
NVNO enVVeno Medical	0.00%	-5.19%	+1.78%	-3.65%	-74.87%
NXL Nexalin Technology	0.00%	-5.11%	-29.04%	-12.07%	-53.88%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
FEMY Femasys	2.50	Moderate Buy	$50.00	1,589.19% Upside
FLGC Flora Growth	1.00	Sell	N/A	N/A
NVNO enVVeno Medical	2.33	Hold	N/A	N/A
NXL Nexalin Technology	1.00	Sell	N/A	N/A

Current Analyst Ratings Breakdown

Latest FLGC, FEMY, NVNO, and NXL Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/18/2026	NXL Nexalin Technology	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
8/18/2026	FEMY Femasys	Lake Street Capital Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Buy	$10.00
8/17/2026	FEMY Femasys	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
8/14/2026	FEMY Femasys	Maxim Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Buy	$10.00
7/31/2026	FEMY Femasys	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
7/16/2026	FEMY Femasys	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
7/8/2026	NXL Nexalin Technology	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)
7/7/2026	NVNO enVVeno Medical	Zacks Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Hold
7/6/2026	NVNO enVVeno Medical	LADENBURG THALM/SH SH Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Hold ➝ Strong-Buy
6/30/2026	NVNO enVVeno Medical	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
6/15/2026	NVNO enVVeno Medical	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)

(Data available from 8/23/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
FEMY Femasys	$2.29M	10.83	N/A	N/A	$0.48 per share	6.17
FLGC Flora Growth	$57.61M	0.09	N/A	N/A	$12.21 per share	0.39
NVNO enVVeno Medical	N/A	N/A	N/A	N/A	$30.28 per share	N/A
NXL Nexalin Technology	$300K	24.40	N/A	N/A	$0.07 per share	4.74

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
FEMY Femasys	-$18.63M	-$3.53	N/A	N/A	N/A	-534.36%	-225.97%	-74.68%	N/A
FLGC Flora Growth	-$15.91M	-$32.49	N/A	N/A	N/A	-32.03%	-64.02%	-34.46%	N/A
NVNO enVVeno Medical	-$19.47M	-$19.33	N/A	N/A	N/A	N/A	-62.28%	-56.83%	10/30/2026 (Estimated)
NXL Nexalin Technology	-$8.22M	-$0.48	N/A	N/A	N/A	-4,141.94%	-278.24%	-218.42%	9/2/2026 (Estimated)

Latest FLGC, FEMY, NVNO, and NXL Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
9/2/2026	Q2 2026	NXL Nexalin Technology	-$0.10	N/A	N/A	N/A	$0.09 million	N/A
8/14/2026	Q2 2026	FEMY Femasys	-$1.31	-$1.33	-$0.02	-$1.33	$0.73 million	$0.33 million
8/12/2026	Q2 2026	NXL Nexalin Technology	-$0.10	-$0.11	-$0.01	-$0.11	$0.09 million	$0.01 million
7/30/2026	Q2 2026	NVNO enVVeno Medical	-$4.69	-$5.37	-$0.68	-$5.37	$1.00 million	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
FEMY Femasys	N/A	N/A	N/A	N/A	N/A
FLGC Flora Growth	N/A	N/A	N/A	N/A	N/A
NVNO enVVeno Medical	N/A	N/A	N/A	N/A	N/A
NXL Nexalin Technology	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
FEMY Femasys	0.89	2.14	1.98
FLGC Flora Growth	N/A	2.08	1.79
NVNO enVVeno Medical	N/A	11.70	11.70
NXL Nexalin Technology	N/A	1.25	1.10

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
FEMY Femasys	65.27%
FLGC Flora Growth	36.01%
NVNO enVVeno Medical	34.71%
NXL Nexalin Technology	0.65%

Insider Ownership

Company	Insider Ownership
FEMY Femasys	7.75%
FLGC Flora Growth	2.34%
NVNO enVVeno Medical	15.00%
NXL Nexalin Technology	16.94%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
FEMY Femasys	30	8.38 million	7.73 million	Not Optionable
FLGC Flora Growth	280	1.05 million	1.02 million	Not Optionable
NVNO enVVeno Medical	30	680,000	581,000	No Data
NXL Nexalin Technology	3	22.04 million	18.30 million	Not Optionable

FLGC, FEMY, NVNO, and NXL Headlines

Recent News About These Companies

Nexalin Technology Raises Liquidity via Short-Term Note

August 21 at 6:10 PM | tipranks.com

Nexalin Announces Capital Raise and Flexible Equity Facility

August 20 at 6:11 PM | tipranks.com

Nexalin Faces New Nasdaq Equity Deficiency, Delisting Risk

August 17, 2026 | tipranks.com

Nexalin Expands and Extends Houston Headquarters Lease Commitment

July 29, 2026 | tipranks.com

Nexalin Appeals Nasdaq Delisting Following Compliance Shortfalls

July 27, 2026 | tipranks.com

Nexalin Technology Corporate Event Calendar | NASDAQ:NXL

July 15, 2026 | benzinga.com

Nexalin Technology Announces that the Investigator of Its Brazilian Clinical Trial Received the Young Researcher Award at BRAIN 2026 for Research Evaluating the Company’s ...

June 23, 2026 | finance.yahoo.com

Nexalin Technology Announces that the Investigator of Its Brazilian Clinical Trial Received the Young Researcher Award at BRAIN 2026 for Research Evaluating the Company's Proprietary DIFS™ Platform

June 23, 2026 | globenewswire.com

Nexalin Overhauls Bylaws, Modernizes Corporate Governance Framework

June 17, 2026 | tipranks.com

Nexalin Technology Announces Two Clinical Abstracts Accepted for Presentation at the 2026 NYC Neuromodulation Conference Highlighting Preliminary Clinical Results Across ...

June 16, 2026 | markets.businessinsider.com

Nexalin Technology, Inc. Announces Acceptance of Clinical Abstracts Showcasing DIFS™ Treatment Efficacy at 2026 NYC Neuromodulation Conference

June 16, 2026 | quiverquant.comQ

Nexalin Technology Announces Two Clinical Abstracts Accepted for Presentation at the 2026 NYC Neuromodulation Conference Highlighting Preliminary Clinical Results Across Anxiety, Depression, Insomnia and Quality of Life

June 16, 2026 | globenewswire.com

Nexalin Technology Reports Compelling Clinical Trial Results in Brazil to Support Product Launch. Trial Demonstrates 77.8% Anxiety Response Rate and Durable Benefits Across ...

June 10, 2026 | finance.yahoo.com

Nexalin Technology, Inc. Reports Successful Clinical Trial Results for Non-Invasive Neurostimulation Treatment of Anxiety and Depression

June 10, 2026 | quiverquant.comQ

Nexalin Technology Reports Compelling Clinical Trial Results in Brazil to Support Product Launch. Trial Demonstrates 77.8% Anxiety Response Rate and Durable Benefits Across Depression, Insomnia and Quality of Life as Company Advances Brazilian Sales Plan.

June 10, 2026 | globenewswire.com

Nexalin Technology Announces Issuance of U.S. Patent Covering Dynamic Frequency Stimulation for Anxiety, Depression and Insomnia

June 4, 2026 | globenewswire.com

Nexalin Technology Secures Key Neurostimulation Legislative Provision & Commends U.S. House-Passed Report Language Expanding Non-Invasive Deep Brain Neurostimulation Research ...

May 21, 2026 | markets.businessinsider.com

Nexalin Technology Secures Key Neurostimulation Legislative Provision & Commends U.S. House-Passed Report Language Expanding Non-Invasive Deep Brain Neurostimulation Research at the Department of Veterans Affairs for Traumatic Brain Injury

May 21, 2026 | globenewswire.com

Nexalin Technology, Inc.: Nexalin Acquires AI-Integrated Digital Health Platform Behind HALO Clarity and Nexalin NeuroCare Ahead of Planned FDA Pivotal Trial

May 20, 2026 | finanznachrichten.de

Nexalin Acquires AI-Integrated Digital Health Platform Behind HALO™ Clarity and Nexalin NeuroCare™ Ahead of Planned FDA Pivotal Trial

May 19, 2026 | globenewswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

FLGC, FEMY, NVNO, and NXL Company Descriptions

Femasys NASDAQ:FEMY

$2.96 +0.23 (+8.42%)

As of 08/21/2026 04:00 PM Eastern

Femasys Inc., a biomedical company, develops therapeutic and diagnostic solutions to address unmet women healthcare needs worldwide. The company provides FemVue saline-air device, a contrast-generating product in the United States, Canada, Japan, and Hong Kong; FemCath, a cornual balloon catheter, a single intrauterine directional delivery product that allows for selective evaluation of an individual fallopian tube; and FemCerv, a biopsy device for endocervical curettage, which can be used to sample cervical cells and tissue circumferentially with sample containment within the device to minimize contamination. It also develops permanent birth control solutions, such as FemBloc and FemChec; FemaSeed, an artificial insemination solution; and FemEMB, a product candidate for endometrial sampling in support of uterine cancer detection testing. The company offers its products to reproductive endocrinologists for infertility products, obstetrics-gynecological physicians, related healthcare professionals, and women's healthcare provider organizations. Femasys Inc. was incorporated in 2004 and is headquartered in Suwanee, Georgia.

Flora Growth NASDAQ:FLGC

$4.71 -1.18 (-20.03%)

As of 08/21/2026

Flora Growth Corp., together with its subsidiaries, engages in the growth, cultivation, and development of medicinal cannabis and medicinal cannabis derivative products worldwide. It operates through three segments: House of Brands, Commercial and Wholesale, and Pharmaceuticals. The company cultivates, processes, and supplies medicinal-grade cannabis flower, and cannabis derived medical and wellness products. It also offers food and beverage, nutraceuticals, cannabis accessories and technology, personal care, and wellness; cannabidiol (CBD) derived products, such as gummies, topicals, tinctures, and vape products; cannabis consumption accessories, personal storage, and travel accessories for the vape and dry herbs. In addition, the company manufactures and distributes pharmaceutical goods and medical cannabis products to treat a variety of health indications, including drugs related to cancer therapies, attention-deficit/hyperactivity disorder, multiple sclerosis, and anti-depressants. The company sells its products under the JustCBD, Vessel, and Phatebo brands. Flora Growth Corp. was incorporated in 2019 and is based in Fort Lauderdale, Florida.

enVVeno Medical NASDAQ:NVNO

$10.29 -0.10 (-0.96%)

As of 08/21/2026 03:34 PM Eastern

enVVeno Medical Corporation (Nasdaq: NVNO) is an medical device company focused on the development of innovative bioprosthetic (tissue-based) devices to improve the standard of care in the treatment of venous disease. The company's lead product, the VenoValve®️, is a first-in-class, surgical implant being developed for the treatment of severe deep venous Chronic Venous Insufficiency (CVI). Deep venous CVI occurs when valves inside of the deep veins of the leg become damaged, resulting in insufficient blood being returned to the heart. The malfunctioning vein valves cause blood to flow backwards (reflux) and pool in the lower leg, increasing the pressure within the veins of the leg (venous hypertension). In the most severe cases, CVI can lead to venous ulcers (open skin sores) that become chronic and difficult to heal. The VenoValve is implanted in the femoral vein and works as a replacement venous valve, designed to reduce reflux and venous hypertension, and to restore proper directional blood flow back to the heart. With severe deep venous CVI impacting an estimated 2.4 million people in the U.S., who have no effective treatment options, the VenoValve has received Breakthrough Device Designation from the U.S. Food and Drug Administration, and is currently being evaluated in the SAVVE U.S. clinical trial.

Nexalin Technology NASDAQ:NXL

$0.33 +0.00 (+0.45%)

As of 08/21/2026 04:00 PM Eastern

Nexalin Technology, Inc., a medical device company, designs and develops neurostimulation products for the treatment of mental health in the United States and China. The company designs and develops Generation 2 and Generation 3, that is in clinical trials for the treatment of substance abuse issues related to opiate, cocaine, alcohol abuse, alzheimer's disease, and dementia. It also licenses and sells Nexalin Device, a non-invasive and undetectable to the human body that can provide relief to its afflicted with mental health issues. The company is based in Houston, Texas.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest FLGC, FEMY, NVNO, and NXL Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest FLGC, FEMY, NVNO, and NXL Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

FLGC, FEMY, NVNO, and NXL Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

FLGC, FEMY, NVNO, and NXL Company Descriptions

Femasys NASDAQ:FEMY

Flora Growth NASDAQ:FLGC

enVVeno Medical NASDAQ:NVNO

Nexalin Technology NASDAQ:NXL

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest FLGC, FEMY, NVNO, and NXL Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest FLGC, FEMY, NVNO, and NXL Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

FLGC, FEMY, NVNO, and NXL Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

FLGC, FEMY, NVNO, and NXL Company Descriptions

Femasys NASDAQ:FEMY

Flora Growth NASDAQ:FLGC

enVVeno Medical NASDAQ:NVNO

Nexalin Technology NASDAQ:NXL

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools